Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma
Name:
Email:

Yes, in addition to e-alerts, please sign me up to receive Nutra Pharma Blog postings via email.
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Research
Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application
 
 
Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom
 
 
Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins
 
 
A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia
 
 
A short-chain a-neurotoxin from Naja najaatra produces potent cholinergic-dependent analgesia
 
Quick Nav
 
Recent News
August 14, 2008
Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)

August 6, 2008
Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)

August 1, 2008
August 2008 Shareholder Letter from Chairman and CEO Rik J. Deitsch
 
 
Announcements
Click Here for an Update on the Phase IIb Clinical Trial Data.
 
 
NPC
Privacy Policy
© 2007-2008, Nutra Pharma Corporation. All Rights Reserved.